<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Schizophrenia - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .header-dates {
            display: flex;
            flex-wrap: wrap;
            gap: 10px;
            margin-top: 16px;
            padding-top: 12px;
            border-top: 1px solid rgba(255,255,255,0.22);
            position: relative;
        }

        .date-chip {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            background: rgba(255,255,255,0.14);
            border: 1px solid rgba(255,255,255,0.25);
            border-radius: 999px;
            padding: 5px 10px;
            font-size: 0.82rem;
        }

        .date-chip-label {
            font-weight: 600;
            opacity: 0.95;
        }

        .date-chip time {
            font-variant-numeric: tabular-nums;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "‚Ü≥ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Schizophrenia</span>
        </nav>

        <header class="page-header">
            <h1>Schizophrenia</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Psychiatric</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0005090" target="_blank">
                        MONDO:0005090
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Psychotic Disorder</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Mental Health Disorder</span>
                
            </div>
            
            
            <div class="header-dates">
                
                <span class="date-chip">
                    <span class="date-chip-label">Entry created</span>
                    <time datetime="2025-12-04T16:57:31Z">2025-12-04</time>
                </span>
                
                
                <span class="date-chip">
                    <span class="date-chip-label">Last updated</span>
                    <time datetime="2026-01-26T15:28:38Z">2026-01-26</time>
                </span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Pathophysiology</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">7</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">11</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">psychiatric disorder</span>
                    
                </div>
            </div>
            
            
            
            
            
            
        </div>
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">7</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Dysregulation of Dopamine Neurotransmission</div>
                
                <div class="item-desc">Imbalance in dopamine transmission in the brain, particularly in the mesolimbic and mesocortical pathways.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        dopamine secretion
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0014046" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        striatum
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27206569" target="_blank">PMID:27206569</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Findings have converged to suggest early dysregulation in the striatum, especially in the rostral caudate, manifesting as excess synthesis and release. Recent data showed deficit extending to most cortical regions and even to other extrastriatal subcortical regions not previously considered to..."</div>
                
                
                <div class="evidence-explanation">While the literature supports dopamine dysregulation in various brain regions, it does not specifically emphasize the mesolimbic and mesocortical pathways alone.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24986384" target="_blank">PMID:24986384</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic)."</div>
                
                
                <div class="evidence-explanation">The abstract does not provide specific information supporting the imbalance of dopamine transmission specifically in the mesolimbic and mesocortical pathways as described in the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/1981107" target="_blank">PMID:1981107</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This article discusses the possibility that a deficient activity within the cortico-striatal glutamatergic pathway is an important pathophysiological component in some cases of schizophrenia and that glutamatergic agonists may prove beneficial in this disorder."</div>
                
                
                <div class="evidence-explanation">The study focuses on glutamate dysregulation rather than dopamine transmission dysregulation in mesolimbic and mesocortical pathways.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Abnormality of Glutamergic Signaling</div>
                
                <div class="item-desc">Dysfunction in glutamate neurotransmission, impacting synaptic plasticity and brain circuit function.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        parvalbumin-positive interneuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000099" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        synaptic transmission, glutamatergic
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0035249" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        prefrontal cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000451" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        hippocampus
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11532718" target="_blank">PMID:11532718</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Research has implicated dysfunction of glutamatergic neurotransmission in the pathophysiology of schizophrenia."</div>
                
                
                <div class="evidence-explanation">The literature specifically states that glutamatergic neurotransmission dysfunction is associated with the pathophysiology of schizophrenia, supporting the provided statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28754595" target="_blank">PMID:28754595</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Accumulating evidence suggests that synaptic plasticity is impaired in schizophrenia. Given the role of synaptic plasticity in learning, memory, and neural circuit maturation, impaired plasticity may underlie many features of the schizophrenia syndrome."</div>
                
                
                <div class="evidence-explanation">The literature discusses the impairment of synaptic plasticity in schizophrenia and its interaction with brain maturation, aligning with the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29954475" target="_blank">PMID:29954475</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Psychosis is now widely hypothesized to involve neural networks beyond the classical dopaminergic mesolimbic pathway, including serotonin and glutamate systems as well."</div>
                
                
                <div class="evidence-explanation">This reference supports the involvement of glutamatergic systems in schizophrenia, reinforcing the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Abnormality of GABAergic Signaling</div>
                
                <div class="item-desc">Dysfunction in GABAergic inhibitory neurotransmission, contributing to excitatory/inhibitory (E/I) imbalance in cortical circuits.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        parvalbumin-positive interneuron
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000099" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        synaptic transmission, GABAergic
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0051932" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        prefrontal cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000451" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/10372507" target="_blank">PMID:10372507</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"At the cellular level, gamma-aminobutyric acid (GABA)-ergic interneurons are a common feature in psychotic states... and are themselves synchronised by the ascending dopamine and serotonin innervations."</div>
                
                
                <div class="evidence-explanation">The literature highlights that GABAergic interneurons play a significant role in the cellular characteristics found in psychotic states, including schizophrenia.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22308256" target="_blank">PMID:22308256</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Disturbances in glutamate and GABAergic neurotransmission may underlie the pathophysiology of schizophrenia."</div>
                
                
                <div class="evidence-explanation">This reference directly states that disturbances in GABAergic neurotransmission may underlie the pathophysiology of schizophrenia.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34584230" target="_blank">PMID:34584230</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Reduced GABA levels indicate that the disruption of excitatory/inhibitory balance may be related to the pathophysiology of schizophrenia-spectrum disorders."</div>
                
                
                <div class="evidence-explanation">This meta-analysis supports the idea that reduced GABA levels and thus GABAergic dysfunction are related to the pathophysiology of schizophrenia.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Complement-Mediated Excessive Synaptic Pruning</div>
                
                <div class="item-desc">Excessive elimination of synapses by microglia via complement component C4A and CR3 pathways during adolescent brain development.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        microglial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000129" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        complement activation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006956" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        synapse pruning
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0098883" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        prefrontal cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000451" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        hippocampus
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Oligodendrocyte and Myelin Dysfunction</div>
                
                <div class="item-desc">Abnormalities in oligodendrocytes and myelin sheaths leading to white matter changes and network dysconnectivity across brain regions.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        oligodendrocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000128" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        myelination
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0042552" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        prefrontal cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000451" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        hippocampus
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Mitochondrial Dysfunction and Oxidative Stress</div>
                
                <div class="item-desc">Bioenergetic deficits including complex I inhibition, decreased glutathione, increased lactate, and oxidative/nitrosative stress creating a feed-forward cycle with neuroinflammation.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        oxidative phosphorylation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006119" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        cellular response to oxidative stress
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0034599" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        prefrontal cortex
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000451" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Blood-Brain Barrier Dysfunction</div>
                
                <div class="item-desc">Increased BBB permeability with elevated CSF albumin and immunoglobulins, involving dysfunction of endothelial cells, pericytes, and astrocytes in the neurovascular unit.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        endothelial cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000115" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        astrocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000127" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        blood-brain barrier
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="graph-warning">
                <strong>Referential integrity issues (1):</strong>
                <ul>
                    
                    <li>Target &#39;Psychotic Symptoms&#39; (from &#39;Dysregulation of Dopamine Neurotransmission&#39;) not found in named elements</li>
                    
                    
                </ul>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Dysregulation_of_Dopamine_Neurotransmission[&#34;Dysregulation of Dopamine Neurotransmission&#34;]
    Psychotic_Symptoms[&#34;Psychotic Symptoms&#34;]

    Dysregulation_of_Dopamine_Neurotransmission -.-&gt; Psychotic_Symptoms

    style Dysregulation_of_Dopamine_Neurotransmission fill:#dbeafe
    style Psychotic_Symptoms fill:#fee2e2,stroke:#dc2626,stroke-dasharray: 5 5</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">7</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Nervous System<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Other<span class="pill-count">(5)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Nervous System
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hallucinations
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000738" target="_blank">
                                Hallucinations
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000738)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Often auditory in nature, such as hearing voices. Can also be visual, tactile, or olfactory.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28437056" target="_blank">PMID:28437056</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Schizophrenia symptoms fall into six common symptom clusters: delusions and hallucinations, disorganization of speech, cognitive dysfunction, negative symptoms, affective symptoms, and motor system abnormalities."</div>
                
                
                <div class="evidence-explanation">Delusions and hallucinations are recognized as common symptom clusters in schizophrenia, supporting the statement that hallucinations are frequent and a part of the psychiatric diagnostic category.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/25773224" target="_blank">PMID:25773224</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Schizophrenia is a complex mental disorder associated with not only cognitive dysfunctions, such as memory and attention deficits, but also changes in basic sensory processing."</div>
                
                
                <div class="evidence-explanation">This supports the note that hallucinations in schizophrenia can be auditory, visual, tactile, or olfactory in nature, indicating changes in sensory processing.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21545448" target="_blank">PMID:21545448</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Prevalence of OHs and hallucinations in other modalities differed according to the WHO-10 international centre. Across centres, OHs were present in 13% of the WHO-10 dataset, similar to the 17% prevalence rate in the SAPS/SANS dataset."</div>
                
                
                <div class="evidence-explanation">This supports the claim that olfactory hallucinations are among the types of hallucinations experienced by schizophrenic patients, although less frequent than auditory hallucinations.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Delusions
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000746" target="_blank">
                                Delusion
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000746)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">False beliefs, often paranoid or grandiose in nature. Resistant to contradictory evidence.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33485408" target="_blank">PMID:33485408</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Delusions are commonly conceived as false beliefs that are held with certainty and which cannot be corrected. This conception of delusion has been influential throughout the history of psychiatry and continues to inform how delusions are approached in clinical practice and in contemporary..."</div>
                
                
                <div class="evidence-explanation">The literature describes delusions as false beliefs that are resistant to contradictory evidence, which aligns with the statement&#39;s note that delusions in schizophrenia are often paranoid or grandiose in nature.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/949230" target="_blank">PMID:949230</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The underlying diagnosis of Capgras delusion is not found to be exclusively paranoid schizophrenia, nor is the sex exclusively female, as once was believed."</div>
                
                
                <div class="evidence-explanation">While Capgras delusion may involve delusions, the reference suggests that these delusions are not exclusively found in paranoid schizophrenia. This partially supports the statement but adds another layer of complexity.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29151090" target="_blank">PMID:29151090</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Non-bizarre delusion, defined as a false belief possible although highly unlikely, is the main manifestation of delusional disorders, previously known as paranoia."</div>
                
                
                <div class="evidence-explanation">The description of non-bizarre delusions aligns with the statement that delusions, which are false beliefs, are a frequent psychiatric diagnostic category in schizophrenia.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">5</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Disorganized Thinking
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Impaired logical thought process and communication. May manifest as loose associations or incoherent speech.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30488088" target="_blank">PMID:30488088</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Disorganized speech is one of the key symptoms of schizophrenia. This article provides an overview of those areas of speech and communication impaired in patients with schizophrenia."</div>
                
                
                <div class="evidence-explanation">Disorganized thinking is closely related to disorganized speech, which is highlighted as a frequent impairment in schizophrenia.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/2084786" target="_blank">PMID:2084786</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The course of psychoses of schizophrenic type follows rules which are still not adequately understood. It is, however, clear that certain symptoms appear mostly early, others only late... we studied 44 final phase patients whose main symptom was disordered thinking of the schizophasic type."</div>
                
                
                <div class="evidence-explanation">The study highlights disordered thinking (a form of cognitive impairment) as a main symptom in later stages of schizophrenia.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37040138" target="_blank">PMID:37040138</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Patients with schizophrenia were impaired in both analytic and common-sense thinking."</div>
                
                
                <div class="evidence-explanation">Impaired logical thought processes and communication, which might manifest as loose associations or incoherent speech, align with the cognitive phenotype of disorganized thinking.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Social Withdrawal
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Reduction in social interactions and engagement. Can lead to isolation and difficulty maintaining relationships.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31390645" target="_blank">PMID:31390645</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A &#39;positively withdrawn&#39; position characterizes a wider group of patients than originally reported. Further, we identified a preference for partaking in social activities in particular circumstances with clearly circumscribed goals or social roles and rules."</div>
                
                
                <div class="evidence-explanation">The study indicates that social withdrawal is a significant aspect of schizophrenia and is frequently observed among patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35102081" target="_blank">PMID:35102081</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Social withdrawal was measured by a specific item of the Heinrichs-Carpenter Quality of Life Scale. Social withdrawal was associated with a lower score in the neurocognitive composite score and in &#39;Verbal memory,&#39; &#39;Processing speed&#39; and &#39;Working memory&#39; scores."</div>
                
                
                <div class="evidence-explanation">The study confirms the association between social withdrawal and various neurocognitive deficits in schizophrenia, supporting its frequent occurrence.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11103877" target="_blank">PMID:11103877</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Negative symptoms encompass, among others, anhedonia, flat affect, avolition and social withdrawal."</div>
                
                
                <div class="evidence-explanation">The review details social withdrawal as a prominent negative symptom in schizophrenia, further corroborating its frequent occurrence.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Flat Affect
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Reduced expression of emotions. May appear unresponsive or lacking emotional depth.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16452608" target="_blank">PMID:16452608</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Impaired emotional functioning in schizophrenia is a prominent clinical feature that manifests primarily as flat affect... Flat affect was more common in men and was associated with poorer premorbid adjustment, worse current quality of life, and worse outcome at 1-year follow-up."</div>
                
                
                <div class="evidence-explanation">The study provides evidence that flat affect is a frequent and prominent clinical feature of schizophrenia, which aligns with the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23846857" target="_blank">PMID:23846857</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Schizophrenia probands showed more symptoms and lower psychosocial functioning than probands with psychotic bipolar disorder, but there was considerable overlap in clinical manifestations."</div>
                
                
                <div class="evidence-explanation">The reference suggests that flat affect, which is an emotional deficit, is part of the clinical phenotype of schizophrenia.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31839552" target="_blank">PMID:31839552</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Voice atypicalities have been a characteristic feature of schizophrenia ... They are often associated with core negative symptoms such as flat affect and alogia ... This suggests that voice atypicalities may represent a marker of clinical features and social functioning in schizophrenia."</div>
                
                
                <div class="evidence-explanation">The study mentions flat affect as one of the core negative symptoms of schizophrenia, supporting its frequent occurrence within the schizophrenia phenotype.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Working Memory Deficits
                        
                        <span class="phenotype-freq">COMMON</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Difficulties in short-term information storage and manipulation.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36252418" target="_blank">PMID:36252418</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Our data gives preliminary support to the hypotheses that there is a working memory deficit phenotype within the syndrome of schizophrenia with has a biological underpinning."</div>
                
                
                <div class="evidence-explanation">Evidence suggests there is a working memory deficit phenotype within schizophrenia.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30104335" target="_blank">PMID:30104335</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"PFC dysfunction is widely believed to underlie working memory (WM) deficits in people with schizophrenia (PSZ)...These results indicate that PPC dysfunction is central to WM storage deficits in PSZ and may play a key role in the broad cognitive deficits associated with schizophrenia."</div>
                
                
                <div class="evidence-explanation">The literature highlights WM deficits as a central part of cognitive impairment in schizophrenia.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20053864" target="_blank">PMID:20053864</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Working memory impairment is considered a core deficit in schizophrenia."</div>
                
                
                <div class="evidence-explanation">The study directly supports the existence of working memory deficits as a core phenotype in schizophrenia.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Catatonia
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                    </div>
                    
                    <div class="item-desc">Abnormal motor behavior, ranging from excessive movement to immobility.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11478416" target="_blank">PMID:11478416</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Catatonia is a parallel behavior phenomenon to delusions (in thought) and delirium (in cognition)."</div>
                
                
                <div class="evidence-explanation">The reference suggests catatonia is associated with schizophrenia but does not specify the frequency of this phenotype.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34785041" target="_blank">PMID:34785041</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Lower activity levels correlated with increased age and severity of catatonia and parkinsonism. The 22 patients with catatonia had lower activity as well as higher scores on parkinsonism, involuntary movements, and negative symptoms compared to the 30 patients without catatonia."</div>
                
                
                <div class="evidence-explanation">The study indicates catatonia is present in some patients with schizophrenia but does not specify its frequency.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/22814247" target="_blank">PMID:22814247</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Classical schizophrenia literature reports motor symptoms as characteristic of the disorder... This review of the literature supports the idea that motor symptoms are closely related to the neurodevelopmental disturbances of schizophrenia and a distinct syndromal dimension with its own pathophysiology."</div>
                
                
                <div class="evidence-explanation">The literature suggests catatonia, as a motor symptom, is a recognized aspect of schizophrenia.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">11</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    DRD2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    GRIN1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    GRIN2A
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    GAD1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    RELN
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    C4A
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    C3
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    DISC1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30286368" target="_blank">PMID:30286368</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"DISC1 gene has been shown as a risk factor for schizophrenia in some reports."</div>
                
                
                <div class="evidence-explanation">The meta-analysis confirms associations between specific SNPs in the DISC1 gene and schizophrenia risk.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24056909" target="_blank">PMID:24056909</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Questions about DISC1 as a genetic risk factor for schizophrenia."</div>
                
                
                <div class="evidence-explanation">This reference raises questions about the role of DISC1 as a risk factor, implying a lack of consensus.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30285728" target="_blank">PMID:30285728</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The human DISC1 gene is located on chromosome 1 and is highly associated with schizophrenia and other mental disorders."</div>
                
                
                <div class="evidence-explanation">This study associates the DISC1 gene with schizophrenia among other mental disorders, supporting its role as a risk factor.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    COMT
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23573605" target="_blank">PMID:23573605</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"COMT is an enzyme that is distributed widely throughout the brain, but seems to be uniquely relevant to how dopamine affects information-processing in the prefrontal cortex. There is a common variation in the genetic sequence of the COMT gene, which causes a dramatic change in its enzyme..."</div>
                
                
                <div class="evidence-explanation">The COMT gene is identified as a weak genetic risk factor for schizophrenia, increasing the risk by 50-80% in family studies.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    NRG1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16520822" target="_blank">PMID:16520822</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Our meta-analysis provides support for the association of NRG1 with schizophrenia, but indicates that firmly establishing the role of NRG1 gene in schizophrenia by genetic association requires much larger sample sizes than have hitherto been reported."</div>
                
                
                <div class="evidence-explanation">The meta-analysis found some evidence supporting the association of NRG1 with schizophrenia, but also highlighted the need for larger sample sizes to firmly establish this role.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15162166" target="_blank">PMID:15162166</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Recently, the gene that encodes neuregulin-1 (NRG1) has been identified as a potential susceptibility gene for schizophrenia, and defects in the expression of erbB3, one of the NRG1 receptors, have been shown to occur in the prefrontal cortex of schizophrenic patients..."</div>
                
                
                <div class="evidence-explanation">This reference identifies NRG1 as a potential susceptibility gene for schizophrenia, indicating a genetic association.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20600464" target="_blank">PMID:20600464</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We mainly focus on genes including:...NRG1 (Neuregulin 1)... Taken together there is converging evidence for the contribution of genes potentially related to alterations in intracellular Ca-homeostasis to the risk of schizophrenia."</div>
                
                
                <div class="evidence-explanation">This review points to NRG1 as a gene potentially related to the risk of schizophrenia.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    DTNBP1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19862852" target="_blank">PMID:19862852</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This study shows that DTNBP1 is a risk gene for schizophrenia in EAs. Variation at DTNBP1 may modify risk for schizophrenia in this population."</div>
                
                
                <div class="evidence-explanation">This reference provides evidence that DTNBP1 is associated with an increased risk of schizophrenia, particularly in European-Americans.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/18474210" target="_blank">PMID:18474210</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"To date, DTNBP1 has provided the greatest evidence of illness modification, as associations with negative and cognitive symptoms and worse outcome have been published in independent samples."</div>
                
                
                <div class="evidence-explanation">This reference elaborates on the association of DTNBP1 with specific clinical features of schizophrenia, further supporting its role as a risk factor.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24968777" target="_blank">PMID:24968777</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"It considers models for understanding the role(s) of risk genes, with a particular focus on DTNBP1 and NRG1, their interactions with environmental factors, and with each other (epistasis)."</div>
                
                
                <div class="evidence-explanation">This reference discusses the role of DTNBP1 as a risk gene for schizophrenia within the context of genetic and environmental interactions.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Antipsychotic Medications
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Medications such as risperidone, olanzapine, and clozapine to manage symptoms.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (7 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12769630" target="_blank">PMID:12769630</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"With the use of chlorpromazine and other traditional antipsychotics for psychosis, it was soon discovered that the antipsychotic efficacy of this class of medications was closely associated with their ability to block dopamine D(2) receptors in the brain."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement that antipsychotic medications act through dopamine D2 receptor antagonism. It also mentions medications like clozapine, risperidone, and others, but does not specifically mention olanzapine in this context.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/14514482" target="_blank">PMID:14514482</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                
                <div class="evidence-explanation">The title suggests a focus on schizophrenia treatments, but no abstract provided to verify the contents in relation to the detailed mechanism of action of risperidone, olanzapine, or clozapine.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/8626371" target="_blank">PMID:8626371</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The introduction of novel antipsychotic agents, such as clozapine and risperidone, has enhanced the clinicians&#39; ability to manage schizophrenic patients."</div>
                
                
                <div class="evidence-explanation">This supports the usage of clozapine and risperidone but does not detail the mechanism focused on dopamine D2 receptor antagonism.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 4 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Cognitive Behavioral Therapy (CBT)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000077" target="_blank">
                            MAXO:0000077
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Therapy aimed at changing maladaptive thought patterns and behaviors.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20880828" target="_blank">PMID:20880828</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"There is good evidence from a considerable number of clinical trials that CBTp has a consistent clinical benefit when used in addition to standard care."</div>
                
                
                <div class="evidence-explanation">This indicates that Cognitive Behavioral Therapy (CBT) is a recognized treatment for schizophrenia that aims at changing maladaptive thought patterns and behaviors.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27335156" target="_blank">PMID:27335156</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Cognitive behavioural therapy for psychosis and cognitive remediation are 2 psychosocial interventions that have demonstrated positive outcomes for violence in SCZ."</div>
                
                
                <div class="evidence-explanation">This highlights that CBT, which focuses on changing maladaptive thought patterns and behaviors, is effective in treating certain symptoms of schizophrenia.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17716100" target="_blank">PMID:17716100</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A theoretical analysis of schizophrenia based on a cognitive model integrates the complex interaction of predisposing neurobiological, environmental, cognitive, and behavioral factors with the diverse symptomatology."</div>
                
                
                <div class="evidence-explanation">The statement aligns with the cognitive approach to schizophrenia, which underpins CBT.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Social Skills Training
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000077" target="_blank">
                            MAXO:0000077
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Programs to enhance social interactions and functioning.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (6 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16885207" target="_blank">PMID:16885207</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Social skills training consists of learning activities utilizing behavioral techniques that enable persons with schizophrenia and other disabling mental disorders to acquire interpersonal disease management and independent living skills for improved functioning in their communities."</div>
                
                
                <div class="evidence-explanation">The study states that social skills training helps individuals with schizophrenia to improve functioning in their communities by acquiring interpersonal and independent living skills.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31708048" target="_blank">PMID:31708048</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Common elements to these interventions include building a therapeutic alliance, recovery orientation, education, and skills training, which can be directed to a range of targets, including problem-solving, communication, social skills, and social cognition."</div>
                
                
                <div class="evidence-explanation">Clinical therapies for first-episode psychosis as part of coordinated specialty care (CSC) include skills training directed at social skills.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23773889" target="_blank">PMID:23773889</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"METHODOLOGY: Social skills training, cognitive behavioral therapy, cognitive remediation, and social cognitive training therapy paradigms were searched and the extant literature is summarized for each, with particular focus on: 1) the rationale for treatment methodology; 2) particular methods of..."</div>
                
                
                <div class="evidence-explanation">This reference indicates that social skills training is a recognized psychosocial method used to treat schizophrenia and discusses its efficacy.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 3 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Supportive Therapy
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Ongoing support to help manage daily life and stress.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15176765" target="_blank">PMID:15176765</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"This article posits that the positive findings for supportive therapy (ST) in recent trials may indicate an important but undervalued aspect of psychosocial interventions for schizophrenia."</div>
                
                
                <div class="evidence-explanation">The article discusses the benefits of supportive therapy in schizophrenia treatment and emphasizes mechanisms such as the therapeutic alliance and social support, indicating that ongoing support helps manage daily life and stress.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23244011" target="_blank">PMID:23244011</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The intervention group improved significantly on measures of both PANSS and GAF scores, with large effect sizes at two years follow-up after inclusion. Further, improvement on GAF(function) (p = 0.000) and GAF(symptom) (p = 0.010) significantly favored SPP in combination with TaU over TaU alone."</div>
                
                
                <div class="evidence-explanation">Supportive psychodynamic psychotherapy, a variant of supportive therapy, was found to significantly improve symptoms and functional outcomes, underscoring its role in ongoing support for managing stress and daily life in schizophrenia.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31708048" target="_blank">PMID:31708048</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Group, individual, and family therapies in CSC aim to help the client and family understand and cope with the experience of psychosis, promote symptomatic and functional recovery and improve quality of life, and support the pursuit of personally meaningful goals of the client."</div>
                
                
                <div class="evidence-explanation">Coordinated specialty care, including supportive interventions, focuses on coping, recovery, and quality of life, indicating the importance of ongoing support.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Vocational Rehabilitation
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0001351" target="_blank">
                            MAXO:0001351
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Help with gaining and maintaining employment.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/8749891" target="_blank">PMID:8749891</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Most vocational rehabilitation programs have a positive influence on work-related activities, but most have failed to show substantial and enduring impacts on independent, competitive employment."</div>
                
                
                <div class="evidence-explanation">While vocational rehabilitation programs have positive influences on work-related activities, they have not generally shown substantial and enduring impacts on competitive employment.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31327504" target="_blank">PMID:31327504</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"At the end of two years in the service, 829 (70.4%) patients were meaningfully employed and 348 (29.6%) patients were unemployed."</div>
                
                
                <div class="evidence-explanation">Vocational programs have shown promise with a significant portion of patients being gainfully employed, but it does not necessarily indicate maintaining stable employment over long periods.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/18715755" target="_blank">PMID:18715755</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"NET training improved vocational outcomes, suggesting the value of combining cognitive remediation with other rehabilitation methods to enhance functional outcomes."</div>
                
                
                <div class="evidence-explanation">Neurocognitive enhancement therapy combined with vocational services showed improved employment outcomes, supporting the positive impact on gaining and maintaining employment.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">üåç</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Prenatal Stress</div>
                
                
                <div class="item-desc">Exposure to stress during fetal development may increase risk.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33544627" target="_blank">PMID:33544627</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"we appraise the evidence linking schizophrenia spectrum disorder to prenatal maternal stress."</div>
                
                
                <div class="evidence-explanation">The review provides evidence linking prenatal stress to the risk of schizophrenia spectrum disorder.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26968981" target="_blank">PMID:26968981</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"prenatal stress induces neurodevelopmental alterations in the prefrontal cortex that are expressed as cognitive impairment observed in schizophrenia."</div>
                
                
                <div class="evidence-explanation">The article discusses the association between prenatal stress and neurodevelopmental changes leading to schizophrenia.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26753951" target="_blank">PMID:26753951</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Findings suggest sex-specific fetal sensitivity to maternal reported daily life stress during pregnancy on risk for SSD, with males appearing to be more vulnerable to the influences of maternal stress during pregnancy."</div>
                
                
                <div class="evidence-explanation">The study found that maternal stress during pregnancy is associated with increased risk of schizophrenia spectrum disorders in offspring, particularly males.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Cannabis Use</div>
                
                
                <div class="item-desc">Associated with increased risk and earlier onset in genetically predisposed individuals.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24957864" target="_blank">PMID:24957864</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Although considerable evidence implicates cannabis use as a component cause of schizophrenia, it remains unclear whether this is entirely due to cannabis directly raising risk of psychosis, or whether the same genes that increases psychosis risk may also increase risk of cannabis use."</div>
                
                
                <div class="evidence-explanation">The study suggests that there is an association between cannabis use and schizophrenia, but it indicates that the genetic components might play a significant role, making it partially supportive.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26232243" target="_blank">PMID:26232243</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Individuals with a history of cannabis abuse had an earlier age at onset by nearly six years."</div>
                
                
                <div class="evidence-explanation">The study provides direct evidence that cannabis use is associated with an earlier age at onset of psychosis.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/21068828" target="_blank">PMID:21068828</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"onset is associated with environmental factors such as early life adversity, growing up in an urban environment, minority group position and cannabis use."</div>
                
                
                <div class="evidence-explanation">The association of environmental factors, including cannabis use, supports the idea of increased risk of schizophrenia.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Dopamine Metabolites
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Observed in cerebrospinal fluid and postmortem brain analysis.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39348" target="_blank">PMID:39348</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Elevated levels [of dimethyltryptamine] are found in some cases of schizophrenia and of liver disease."</div>
                
                
                <div class="evidence-explanation">The study mentions elevated levels of the dopamine metabolite dimethyltryptamine in cerebrospinal fluid of schizophrenic patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37271040" target="_blank">PMID:37271040</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"CSF dopamine was reliably detected in 50% of healthy controls and in 65% of first-episode psychosis subjects and significantly higher in first-episode psychosis subjects compared to age-matched healthy controls."</div>
                
                
                <div class="evidence-explanation">This study shows increased cerebrospinal fluid dopamine levels, which are related to dopamine metabolism, in first-episode psychosis subjects, supporting elevated dopamine metabolites in CSF in schizophrenia.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/9278185" target="_blank">PMID:9278185</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The application of this strategy, and its value in overcoming some of the potential pitfalls of postmortem studies, is demonstrated in a series of investigations designed to test the hypothesis that dopamine neurotransmission is impaired in the entorhinal cortex in schizophrenia."</div>
                
                
                <div class="evidence-explanation">While it discusses postmortem brain analysis and dopamine dysfunction in schizophrenia, it does not specifically state elevated dopamine metabolites.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Glutamate Levels
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Observed in cerebrospinal fluid and postmortem brain analysis.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/18366307" target="_blank">PMID:18366307</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Although numerous studies have aimed to identify potential diagnostic markers in the CSF of schizophrenia patients, as yet not one has found its way to clinical application."</div>
                
                
                <div class="evidence-explanation">The study discusses the search for diagnostic markers in CSF but does not provide specific evidence for elevated glutamate levels.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/11684348" target="_blank">PMID:11684348</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Kynurenic acid is an endogenous glutamate antagonist with a preferential action at the glycine-site of the N-methyl D-aspartate-receptor."</div>
                
                
                <div class="evidence-explanation">This study focuses on the elevated levels of kynurenic acid, not directly on glutamate levels.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20846490" target="_blank">PMID:20846490</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Accordingly, it is possible that abnormalities in the biochemical cascades regulated by BH(4) may alter DA, 5-HT and Glu neurotransmission, and consequently contribute to the pathophysiology of different neuropsychiatric diseases including schizophrenia."</div>
                
                
                <div class="evidence-explanation">The study mentions alterations in glutamate (Glu) neurotransmission in schizophrenia, aligning with the statement.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Schizophrenia
creation_date: &#39;2025-12-04T16:57:31Z&#39;
updated_date: &#39;2026-01-26T15:28:38Z&#39;
category: Psychiatric
parents:
- Psychotic Disorder
- Mental Health Disorder
progression:
- phase: Prodromal
  age_range: 15-25
  notes: Subtle changes in thoughts, feelings, and behavior
  evidence:
  - reference: PMID:10225329
    supports: SUPPORT
    snippet: In adolescence, preschizophrenics exhibit subtle changes in cognition and affect as well as a variety of anomalous subjective experiences (so-called &#39;basic symptoms&#39;), suggesting &#39;trait&#39; status of these features.
    explanation: This reference indicates that during adolescence, which overlaps with the 15-25 age range, individuals who are preschizophrenic show subtle changes in their thoughts and feelings, aligning with the prodromal phase as described.
  - reference: PMID:37027026
    supports: SUPPORT
    snippet: EOP patients had significantly more prodromal symptoms with a higher frequency of trouble with thinking, avolition and hallucinations than AOP patients.
    explanation: This study supports the presence of subtle changes in thinking and behavior during the prodromal phase in early-onset psychosis, which includes patients younger than 18, blending into the 15-25 age range.
- phase: Onset
  age_range: 16-30
  notes: First episode of psychosis
  evidence:
  - reference: PMID:7654792
    supports: PARTIAL
    snippet: Early-onset schizophrenias (&lt; or = 20 years) were compared with a medium-onset group (21 - &lt; 35 years) and a late-onset group (35 - &lt; 60 years) with regard to age and type of onset, early symptom-related course, social development and social course.
    explanation: The study provides information about the age of onset and early course of schizophrenia that falls within the 16-30 age range but does not specifically address the entire age range spectrum for the onset of the first episode of psychosis.
  - reference: PMID:20021319
    supports: SUPPORT
    snippet: There are progressive frontal changes in males with adolescent-onset psychosis... Ultra high-risk patients who subsequently develop psychosis and first-episode psychosis patients develop significant grey matter reduction in the planum polare, planum temporale and caudal region; a progressive process in the superior temporal gyrus may precede the first expression of florid psychosis.
    explanation: This literature provides evidence about the progression of schizophrenia, particularly related to brain changes, within the stated age range of 16-30 years during the onset phase of the first episode of psychosis.
  - reference: PMID:10225329
    supports: SUPPORT
    snippet: Prodromal symptoms occur in a substantial proportion of preschizophrenics, followed by a short prepsychotic phase with the crystallization of a psychotic syndrome.
    explanation: This reference supports the progression of schizophrenia during the onset phase and includes the age group that aligns with the 16-30 age range.
  - reference: PMID:26467909
    supports: PARTIAL
    snippet: Patients with first-episode psychosis were found to have high relapse rates during the first years after illness onset.
    explanation: While discussing the progression of symptoms and outcomes following the first episode of psychosis, this study does not focus specifically on the age range of 16-30 years.
- phase: Chronic
  notes: Long-term management of symptoms and functioning
  evidence:
  - reference: PMID:9789265
    supports: SUPPORT
    snippet: Long-term treatment of patients with chronic schizophrenias requires integration of many therapeutic approaches, co-operation of several professions, and regard for the views of patients and relatives.
    explanation: The excerpt supports the idea that managing symptoms and functioning in chronic schizophrenia requires long-term management.
  - reference: PMID:23172002
    supports: PARTIAL
    snippet: The evidence shows that although approximately 25% of people with schizophrenia have a poor long-term outcome, few of these show the incremental loss of function that is characteristic of neurodegenerative illnesses.
    explanation: This statement supports the idea that while a subset of patients experience poor long-term outcomes, most do not have progressive deterioration like in neurodegenerative diseases.
  - reference: PMID:10082190
    supports: SUPPORT
    snippet: The criteria proposed necessitate (i) diagnosis of schizophrenia by standard operational criteria, (ii) continuous hospitalization for at least the past 2 years, (iii) a level of psychosocial functioning of &lt; or = 40 as measured by the Global Assessment Scale, and (iv) an intensity score of &#39;marked&#39; or &#39;severe&#39; on at least three of the six Manchester Scale items.
    explanation: The criteria for refractory schizophrenia include long-term management indicating that managing symptoms and functioning over time is essential.
  - reference: PMID:26168930
    supports: SUPPORT
    snippet: A cluster analysis performed on the resulting similarity matrix yielded two main groups (a &#39;improving&#39; and a &#39;chronic&#39; group), which comprised a total of six different types of illness course.
    explanation: The study&#39;s finding of an &#39;improving&#39; and &#39;chronic&#39; group supports that managing symptoms and functioning is a significant aspect for those in the chronic phase.
prevalence:
- population: global
  percentage: 0.3-0.7
  notes: &#39;male_to_female_ratio: 1.4:1&#39;
  evidence:
  - reference: PMID:18480098
    supports: PARTIAL
    snippet: The rate ratio for males:females was 1.4:1. Prevalence estimates also show prominent variation.
    explanation: While the male to female ratio of incidence is reported as 1.4:1, the abstract does not provide exact figures on the percentage of the population affected except that there is prominent variation. Therefore, the part of the statement with the percentage is not directly supported by this source.
pathophysiology:
- name: Dysregulation of Dopamine Neurotransmission
  synonyms:
  - Dopamine Hypothesis
  description: Imbalance in dopamine transmission in the brain, particularly in the mesolimbic and mesocortical pathways.
  biological_processes:
  - preferred_term: dopamine secretion
    term:
      id: GO:0014046
      label: dopamine secretion
  locations:
  - preferred_term: striatum
  downstream:
  - target: Psychotic Symptoms
    description: Striatal dopamine dysregulation causes abnormal salience attribution resulting in psychotic symptoms.
    evidence:
    - reference: PMID:35390609
      supports: SUPPORT
      snippet: Striatal dopamine dysregulation follows, causing abnormal salience and resultant psychotic symptoms.
      explanation: This 2022 review describes how dopamine dysregulation in the striatum creates abnormal salience attribution which directly results in the psychotic symptoms characteristic of schizophrenia.
  evidence:
  - reference: PMID:27206569
    supports: PARTIAL
    snippet: Findings have converged to suggest early dysregulation in the striatum, especially in the rostral caudate, manifesting as excess synthesis and release. Recent data showed deficit extending to most cortical regions and even to other extrastriatal subcortical regions not previously considered to be &#39;hypodopaminergic&#39; in schizophrenia.
    explanation: While the literature supports dopamine dysregulation in various brain regions, it does not specifically emphasize the mesolimbic and mesocortical pathways alone.
  - reference: PMID:24986384
    supports: NO_EVIDENCE
    snippet: &#39;A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic).&#39;
    explanation: The abstract does not provide specific information supporting the imbalance of dopamine transmission specifically in the mesolimbic and mesocortical pathways as described in the statement.
  - reference: PMID:1981107
    supports: NO_EVIDENCE
    snippet: This article discusses the possibility that a deficient activity within the cortico-striatal glutamatergic pathway is an important pathophysiological component in some cases of schizophrenia and that glutamatergic agonists may prove beneficial in this disorder.
    explanation: The study focuses on glutamate dysregulation rather than dopamine transmission dysregulation in mesolimbic and mesocortical pathways.
  - reference: PMID:24128684
    supports: PARTIAL
    snippet: This clinical picture is generally associated with supersensitivity to dopamine, and activates dopamine neurotransmission that is usually alleviated or blocked by drugs that block dopamine D2 receptors.
    explanation: There is an implication of dopamine dysregulation, but the specifics of mesolimbic and mesocortical pathways are not confirmed.
- name: Abnormality of Glutamergic Signaling
  synonyms:
  - Glutamate Hypothesis
  description: Dysfunction in glutamate neurotransmission, impacting synaptic plasticity and brain circuit function.
  cell_types:
  - preferred_term: parvalbumin-positive interneuron
    description: NMDA hypofunction on parvalbumin interneurons leads to cortical disinhibition.
    term:
      id: CL:0000099
      label: interneuron
  biological_processes:
  - preferred_term: synaptic transmission, glutamatergic
    term:
      id: GO:0035249
      label: synaptic transmission, glutamatergic
  locations:
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
  - preferred_term: hippocampus
    term:
      id: UBERON:0001954
      label: Ammon&#39;s horn
  evidence:
  - reference: PMID:11532718
    supports: SUPPORT
    snippet: Research has implicated dysfunction of glutamatergic neurotransmission in the pathophysiology of schizophrenia.
    explanation: The literature specifically states that glutamatergic neurotransmission dysfunction is associated with the pathophysiology of schizophrenia, supporting the provided statement.
  - reference: PMID:28754595
    supports: SUPPORT
    snippet: Accumulating evidence suggests that synaptic plasticity is impaired in schizophrenia. Given the role of synaptic plasticity in learning, memory, and neural circuit maturation, impaired plasticity may underlie many features of the schizophrenia syndrome.
    explanation: The literature discusses the impairment of synaptic plasticity in schizophrenia and its interaction with brain maturation, aligning with the statement.
  - reference: PMID:29954475
    supports: SUPPORT
    snippet: Psychosis is now widely hypothesized to involve neural networks beyond the classical dopaminergic mesolimbic pathway, including serotonin and glutamate systems as well.
    explanation: This reference supports the involvement of glutamatergic systems in schizophrenia, reinforcing the statement.
  - reference: PMID:22351070
    supports: SUPPORT
    snippet: Schizophrenia is believed to result from problems during neural development that lead to improper function of synaptic transmission and plasticity, and in agreement, many of the susceptibility genes encode proteins critical for neural development.
    explanation: The literature supports the idea that schizophrenia impacts synaptic transmission and plasticity, specifically implicating glutamatergic, GABAergic, dopaminergic, and cholinergic synapses.
- name: Abnormality of GABAergic Signaling
  synonyms:
  - GABAergic Dysfunction
  description: Dysfunction in GABAergic inhibitory neurotransmission, contributing to excitatory/inhibitory (E/I) imbalance in cortical circuits.
  cell_types:
  - preferred_term: parvalbumin-positive interneuron
    description: Parvalbumin-positive GABAergic interneurons show reduced function, leading to cortical disinhibition.
    term:
      id: CL:0000099
      label: interneuron
  biological_processes:
  - preferred_term: synaptic transmission, GABAergic
    term:
      id: GO:0051932
      label: synaptic transmission, GABAergic
  locations:
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
  evidence:
  - reference: PMID:10372507
    supports: SUPPORT
    snippet: At the cellular level, gamma-aminobutyric acid (GABA)-ergic interneurons are a common feature in psychotic states... and are themselves synchronised by the ascending dopamine and serotonin innervations.
    explanation: The literature highlights that GABAergic interneurons play a significant role in the cellular characteristics found in psychotic states, including schizophrenia.
  - reference: PMID:22308256
    supports: SUPPORT
    snippet: Disturbances in glutamate and GABAergic neurotransmission may underlie the pathophysiology of schizophrenia.
    explanation: This reference directly states that disturbances in GABAergic neurotransmission may underlie the pathophysiology of schizophrenia.
  - reference: PMID:34584230
    supports: SUPPORT
    snippet: Reduced GABA levels indicate that the disruption of excitatory/inhibitory balance may be related to the pathophysiology of schizophrenia-spectrum disorders.
    explanation: This meta-analysis supports the idea that reduced GABA levels and thus GABAergic dysfunction are related to the pathophysiology of schizophrenia.
  - reference: PMID:25432637
    supports: SUPPORT
    snippet: Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the brain. GABAergic receptor abnormalities have been documented in several major psychiatric disorders including schizophrenia.
    explanation: The abnormalities in GABAergic receptors in schizophrenia support the idea of GABAergic signaling abnormalities being part of the disorder‚Äôs pathophysiology.
  - reference: PMID:22351070
    supports: SUPPORT
    snippet: Here, we will review evidence for altered neurotransmission at ... GABAergic ... synapses in schizophrenia...
    explanation: This article reviews evidence for altered GABAergic neurotransmission in schizophrenia, supporting the stated claim.
- name: Complement-Mediated Excessive Synaptic Pruning
  description: Excessive elimination of synapses by microglia via complement component C4A and CR3 pathways during adolescent brain development.
  cell_types:
  - preferred_term: microglial cell
    description: Microglia eliminate synapses tagged by complement components during critical developmental periods.
    term:
      id: CL:0000129
      label: microglial cell
  biological_processes:
  - preferred_term: complement activation
    term:
      id: GO:0006956
      label: complement activation
  - preferred_term: synapse pruning
    term:
      id: GO:0098883
      label: synapse pruning
  locations:
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
  - preferred_term: hippocampus
    term:
      id: UBERON:0001954
      label: Ammon&#39;s horn
- name: Oligodendrocyte and Myelin Dysfunction
  description: Abnormalities in oligodendrocytes and myelin sheaths leading to white matter changes and network dysconnectivity across brain regions.
  cell_types:
  - preferred_term: oligodendrocyte
    description: Oligodendrocyte dysfunction contributes to impaired myelination and dysconnectivity.
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: myelination
    term:
      id: GO:0042552
      label: myelination
  locations:
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
  - preferred_term: hippocampus
    term:
      id: UBERON:0001954
      label: Ammon&#39;s horn
- name: Mitochondrial Dysfunction and Oxidative Stress
  description: Bioenergetic deficits including complex I inhibition, decreased glutathione, increased lactate, and oxidative/nitrosative stress creating a feed-forward cycle with neuroinflammation.
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
  - preferred_term: cellular response to oxidative stress
    term:
      id: GO:0034599
      label: cellular response to oxidative stress
  locations:
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
- name: Blood-Brain Barrier Dysfunction
  description: Increased BBB permeability with elevated CSF albumin and immunoglobulins, involving dysfunction of endothelial cells, pericytes, and astrocytes in the neurovascular unit.
  cell_types:
  - preferred_term: endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  locations:
  - preferred_term: blood-brain barrier
phenotypes:
- category: Psychiatric
  name: Hallucinations
  frequency: FREQUENT
  diagnostic: true
  notes: Often auditory in nature, such as hearing voices. Can also be visual, tactile, or olfactory.
  evidence:
  - reference: PMID:28437056
    supports: SUPPORT
    snippet: &#39;Schizophrenia symptoms fall into six common symptom clusters: delusions and hallucinations, disorganization of speech, cognitive dysfunction, negative symptoms, affective symptoms, and motor system abnormalities.&#39;
    explanation: Delusions and hallucinations are recognized as common symptom clusters in schizophrenia, supporting the statement that hallucinations are frequent and a part of the psychiatric diagnostic category.
  - reference: PMID:25773224
    supports: SUPPORT
    snippet: Schizophrenia is a complex mental disorder associated with not only cognitive dysfunctions, such as memory and attention deficits, but also changes in basic sensory processing.
    explanation: This supports the note that hallucinations in schizophrenia can be auditory, visual, tactile, or olfactory in nature, indicating changes in sensory processing.
  - reference: PMID:21545448
    supports: SUPPORT
    snippet: Prevalence of OHs and hallucinations in other modalities differed according to the WHO-10 international centre. Across centres, OHs were present in 13% of the WHO-10 dataset, similar to the 17% prevalence rate in the SAPS/SANS dataset.
    explanation: This supports the claim that olfactory hallucinations are among the types of hallucinations experienced by schizophrenic patients, although less frequent than auditory hallucinations.
  - reference: PMID:35383683
    supports: PARTIAL
    snippet: We found that a substantial proportion of patients could not clearly distinguish between thinking and hallucinating. The emotional tone of the voices increased in negativity.
    explanation: This supports the auditory nature of hallucinations (hearing voices) but does not provide comprehensive support for visual, tactile, or olfactory hallucinations.
  phenotype_term:
    preferred_term: Hallucinations
    term:
      id: HP:0000738
      label: Hallucinations
- category: Psychiatric
  name: Delusions
  frequency: FREQUENT
  diagnostic: true
  notes: False beliefs, often paranoid or grandiose in nature. Resistant to contradictory evidence.
  evidence:
  - reference: PMID:33485408
    supports: SUPPORT
    snippet: Delusions are commonly conceived as false beliefs that are held with certainty and which cannot be corrected. This conception of delusion has been influential throughout the history of psychiatry and continues to inform how delusions are approached in clinical practice and in contemporary schizophrenia research.
    explanation: The literature describes delusions as false beliefs that are resistant to contradictory evidence, which aligns with the statement&#39;s note that delusions in schizophrenia are often paranoid or grandiose in nature.
  - reference: PMID:949230
    supports: PARTIAL
    snippet: The underlying diagnosis of Capgras delusion is not found to be exclusively paranoid schizophrenia, nor is the sex exclusively female, as once was believed.
    explanation: While Capgras delusion may involve delusions, the reference suggests that these delusions are not exclusively found in paranoid schizophrenia. This partially supports the statement but adds another layer of complexity.
  - reference: PMID:29151090
    supports: SUPPORT
    snippet: Non-bizarre delusion, defined as a false belief possible although highly unlikely, is the main manifestation of delusional disorders, previously known as paranoia.
    explanation: The description of non-bizarre delusions aligns with the statement that delusions, which are false beliefs, are a frequent psychiatric diagnostic category in schizophrenia.
  - reference: PMID:24677735
    supports: SUPPORT
    snippet: Persecutory and/or grandiose delusions were more strongly associated with each offender group compared with non-offenders, most so with late first offenders.
    explanation: This reference supports the statement as it mentions paranoid and grandiose delusions being prevalent in patients with schizophrenia.
  phenotype_term:
    preferred_term: Delusions
    term:
      id: HP:0000746
      label: Delusion
- category: Cognitive
  name: Disorganized Thinking
  frequency: FREQUENT
  diagnostic: true
  notes: Impaired logical thought process and communication. May manifest as loose associations or incoherent speech.
  evidence:
  - reference: PMID:30488088
    supports: SUPPORT
    snippet: Disorganized speech is one of the key symptoms of schizophrenia. This article provides an overview of those areas of speech and communication impaired in patients with schizophrenia.
    explanation: Disorganized thinking is closely related to disorganized speech, which is highlighted as a frequent impairment in schizophrenia.
  - reference: PMID:2084786
    supports: SUPPORT
    snippet: The course of psychoses of schizophrenic type follows rules which are still not adequately understood. It is, however, clear that certain symptoms appear mostly early, others only late... we studied 44 final phase patients whose main symptom was disordered thinking of the schizophasic type.
    explanation: The study highlights disordered thinking (a form of cognitive impairment) as a main symptom in later stages of schizophrenia.
  - reference: PMID:37040138
    supports: SUPPORT
    snippet: Patients with schizophrenia were impaired in both analytic and common-sense thinking.
    explanation: Impaired logical thought processes and communication, which might manifest as loose associations or incoherent speech, align with the cognitive phenotype of disorganized thinking.
  - reference: PMID:35752547
    supports: SUPPORT
    snippet: We conclude that an early drift towards linguistic disorganization/impoverishment of clause complexity-at the granular level of nominal subject per clause-is a distinctive feature of schizophrenia that decreases longitudinally, thus differentiating schizophrenia from other psychotic illnesses with shared phenomenology.
    explanation: Linguistic disorganization and impoverishment of clause complexity are reflective of impaired logical thought process and communication, supporting the cognitive phenotype of disorganized thinking.
  - reference: PMID:17477206
    supports: PARTIAL
    snippet: The data of interest are (a) the failure to find evidence of cognitive impairment in diagnosed paranoid patients...
    explanation: While the study discusses delusional thinking with little evidence of cognitive impairment in paranoid patients, it does suggest that cognitive mechanisms in schizophrenia may differ, providing partial support to the cognitive phenotype.
- category: Occupational
  name: Social Withdrawal
  frequency: FREQUENT
  notes: Reduction in social interactions and engagement. Can lead to isolation and difficulty maintaining relationships.
  evidence:
  - reference: PMID:31390645
    supports: SUPPORT
    snippet: A &#39;positively withdrawn&#39; position characterizes a wider group of patients than originally reported. Further, we identified a preference for partaking in social activities in particular circumstances with clearly circumscribed goals or social roles and rules.
    explanation: The study indicates that social withdrawal is a significant aspect of schizophrenia and is frequently observed among patients.
  - reference: PMID:35102081
    supports: SUPPORT
    snippet: Social withdrawal was measured by a specific item of the Heinrichs-Carpenter Quality of Life Scale. Social withdrawal was associated with a lower score in the neurocognitive composite score and in &#39;Verbal memory,&#39; &#39;Processing speed&#39; and &#39;Working memory&#39; scores.
    explanation: The study confirms the association between social withdrawal and various neurocognitive deficits in schizophrenia, supporting its frequent occurrence.
  - reference: PMID:11103877
    supports: SUPPORT
    snippet: Negative symptoms encompass, among others, anhedonia, flat affect, avolition and social withdrawal.
    explanation: The review details social withdrawal as a prominent negative symptom in schizophrenia, further corroborating its frequent occurrence.
  - reference: PMID:28637195
    supports: SUPPORT
    snippet: Social disability is a defining characteristic of schizophrenia... One component, social disconnection, occurs extensively... Social disconnection is an objective, long-standing lack of social/family relationships and minimal participation in social activities.
    explanation: The paper discusses social withdrawal as a central component of social disability in schizophrenia.
- category: Mood
  name: Flat Affect
  frequency: FREQUENT
  notes: Reduced expression of emotions. May appear unresponsive or lacking emotional depth.
  evidence:
  - reference: PMID:16452608
    supports: SUPPORT
    snippet: Impaired emotional functioning in schizophrenia is a prominent clinical feature that manifests primarily as flat affect... Flat affect was more common in men and was associated with poorer premorbid adjustment, worse current quality of life, and worse outcome at 1-year follow-up.
    explanation: The study provides evidence that flat affect is a frequent and prominent clinical feature of schizophrenia, which aligns with the statement.
  - reference: PMID:23846857
    supports: SUPPORT
    snippet: Schizophrenia probands showed more symptoms and lower psychosocial functioning than probands with psychotic bipolar disorder, but there was considerable overlap in clinical manifestations.
    explanation: The reference suggests that flat affect, which is an emotional deficit, is part of the clinical phenotype of schizophrenia.
  - reference: PMID:31839552
    supports: SUPPORT
    snippet: Voice atypicalities have been a characteristic feature of schizophrenia ... They are often associated with core negative symptoms such as flat affect and alogia ... This suggests that voice atypicalities may represent a marker of clinical features and social functioning in schizophrenia.
    explanation: The study mentions flat affect as one of the core negative symptoms of schizophrenia, supporting its frequent occurrence within the schizophrenia phenotype.
  - reference: PMID:11103877
    supports: SUPPORT
    snippet: In schizophrenia, negative symptoms encompass, among others, anhedonia, flat affect, avolition, and social withdrawal.
    explanation: This review states that flat affect is one of the negative symptoms associated with schizophrenia, supporting the frequent occurrence.
  - reference: PMID:28242515
    supports: SUPPORT
    snippet: Both extreme levels of social anhedonia (SocAnh) and extreme levels of perceptual aberration/magical ideation (PerMag) indicate increased risk for schizophrenia-spectrum disorders and are associated with emotional deficits.
    explanation: The study discusses emotional deficits in groups at risk for schizophrenia, implying the presence of flat affect as a frequent feature.
  - reference: PMID:11122987
    supports: SUPPORT
    snippet: The schizophrenia phenotype has been traditionally defined by chronic psychosis and functional deterioration ... Subtle clinical signs and symptoms, cognitive impairment particularly in attention and memory, and neurophysiologic deficits such as in sensory gating and smooth-pursuit eye movements all define aspects of the schizophrenia phenotype.
    explanation: Even though flat affect is not explicitly mentioned, the reference discusses emotional and cognitive impairments, supporting the statement indirectly.
- category: Cognitive
  name: Working Memory Deficits
  frequency: COMMON
  notes: Difficulties in short-term information storage and manipulation.
  evidence:
  - reference: PMID:36252418
    supports: SUPPORT
    snippet: Our data gives preliminary support to the hypotheses that there is a working memory deficit phenotype within the syndrome of schizophrenia with has a biological underpinning.
    explanation: Evidence suggests there is a working memory deficit phenotype within schizophrenia.
  - reference: PMID:30104335
    supports: SUPPORT
    snippet: PFC dysfunction is widely believed to underlie working memory (WM) deficits in people with schizophrenia (PSZ)...These results indicate that PPC dysfunction is central to WM storage deficits in PSZ and may play a key role in the broad cognitive deficits associated with schizophrenia.
    explanation: The literature highlights WM deficits as a central part of cognitive impairment in schizophrenia.
  - reference: PMID:20053864
    supports: SUPPORT
    snippet: Working memory impairment is considered a core deficit in schizophrenia.
    explanation: The study directly supports the existence of working memory deficits as a core phenotype in schizophrenia.
  - reference: PMID:19328655
    supports: SUPPORT
    snippet: It is characterized by an admixture of positive, negative, cognitive, mood, and motor symptoms whose severity varies across patients and through the course of the illness.
    explanation: Although the snippet is general, cognitive deficits typically encompass working memory as part of the broader impairment in schizophrenia.
- category: Behavioral
  name: Catatonia
  frequency: OCCASIONAL
  notes: Abnormal motor behavior, ranging from excessive movement to immobility.
  evidence:
  - reference: PMID:11478416
    supports: PARTIAL
    snippet: Catatonia is a parallel behavior phenomenon to delusions (in thought) and delirium (in cognition).
    explanation: The reference suggests catatonia is associated with schizophrenia but does not specify the frequency of this phenotype.
  - reference: PMID:34785041
    supports: PARTIAL
    snippet: Lower activity levels correlated with increased age and severity of catatonia and parkinsonism. The 22 patients with catatonia had lower activity as well as higher scores on parkinsonism, involuntary movements, and negative symptoms compared to the 30 patients without catatonia.
    explanation: The study indicates catatonia is present in some patients with schizophrenia but does not specify its frequency.
  - reference: PMID:22814247
    supports: SUPPORT
    snippet: Classical schizophrenia literature reports motor symptoms as characteristic of the disorder... This review of the literature supports the idea that motor symptoms are closely related to the neurodevelopmental disturbances of schizophrenia and a distinct syndromal dimension with its own pathophysiology.
    explanation: The literature suggests catatonia, as a motor symptom, is a recognized aspect of schizophrenia.
  - reference: PMID:30177576
    supports: SUPPORT
    snippet: Symptoms specific to schizophrenia include self-disturbances, delusional perception and loosening of associations.
    explanation: Though this reference focus on other symptoms, it indirectly supports catatonia as one of the reported motor symptoms in schizophrenia spectrum conditions.
  - reference: PMID:37655417
    supports: PARTIAL
    snippet: &#39;Three forms of periodic catatonia have been identified: hypokinetic, parakinetic, multikinetic.&#39;
    explanation: The study supports the presence of catatonia in schizophrenia but does not clarify the frequency.
  - reference: PMID:20587767
    supports: NO_EVIDENCE
    snippet: Case reports in which abrupt clozapine discontinuation led to a return of psychosis, autonomic instability, or catatonia.
    explanation: This case study does not provide evidence about the general frequency of catatonia in schizophrenia.
biochemical:
- name: Dopamine Metabolites
  presence: Elevated
  context: Observed in cerebrospinal fluid and postmortem brain analysis.
  evidence:
  - reference: PMID:39348
    supports: SUPPORT
    snippet: Elevated levels [of dimethyltryptamine] are found in some cases of schizophrenia and of liver disease.
    explanation: The study mentions elevated levels of the dopamine metabolite dimethyltryptamine in cerebrospinal fluid of schizophrenic patients.
  - reference: PMID:37271040
    supports: SUPPORT
    snippet: CSF dopamine was reliably detected in 50% of healthy controls and in 65% of first-episode psychosis subjects and significantly higher in first-episode psychosis subjects compared to age-matched healthy controls.
    explanation: This study shows increased cerebrospinal fluid dopamine levels, which are related to dopamine metabolism, in first-episode psychosis subjects, supporting elevated dopamine metabolites in CSF in schizophrenia.
  - reference: PMID:9278185
    supports: PARTIAL
    snippet: The application of this strategy, and its value in overcoming some of the potential pitfalls of postmortem studies, is demonstrated in a series of investigations designed to test the hypothesis that dopamine neurotransmission is impaired in the entorhinal cortex in schizophrenia.
    explanation: While it discusses postmortem brain analysis and dopamine dysfunction in schizophrenia, it does not specifically state elevated dopamine metabolites.
  - reference: PMID:18366307
    supports: NO_EVIDENCE
    snippet: Although numerous studies have aimed to identify potential diagnostic markers in the CSF of schizophrenia patients, as yet not one has found its way to clinical application.
    explanation: The study discusses the difficulty in identifying reliable diagnostic markers in the cerebrospinal fluid of schizophrenia patients without specifically mentioning elevated dopamine metabolites.
- name: Glutamate Levels
  presence: Elevated
  context: Observed in cerebrospinal fluid and postmortem brain analysis.
  evidence:
  - reference: PMID:18366307
    supports: NO_EVIDENCE
    snippet: Although numerous studies have aimed to identify potential diagnostic markers in the CSF of schizophrenia patients, as yet not one has found its way to clinical application.
    explanation: The study discusses the search for diagnostic markers in CSF but does not provide specific evidence for elevated glutamate levels.
  - reference: PMID:11684348
    supports: NO_EVIDENCE
    snippet: Kynurenic acid is an endogenous glutamate antagonist with a preferential action at the glycine-site of the N-methyl D-aspartate-receptor.
    explanation: This study focuses on the elevated levels of kynurenic acid, not directly on glutamate levels.
  - reference: PMID:20846490
    supports: SUPPORT
    snippet: Accordingly, it is possible that abnormalities in the biochemical cascades regulated by BH(4) may alter DA, 5-HT and Glu neurotransmission, and consequently contribute to the pathophysiology of different neuropsychiatric diseases including schizophrenia.
    explanation: The study mentions alterations in glutamate (Glu) neurotransmission in schizophrenia, aligning with the statement.
  - reference: PMID:37752221
    supports: SUPPORT
    snippet: A subgroup of patients with schizophrenia is believed to have aberrant excess of glutamate in the frontal cortex.
    explanation: The study provides evidence of elevated glutamate levels in the frontal cortex in schizophrenia patients.
  - reference: PMID:17156977
    supports: NO_EVIDENCE
    snippet: Levels of L-serine, L-glutamine and L-glutamate were unaffected.
    explanation: The study reported no significant change in glutamate levels in the brain of schizophrenia patients, contrasting with the statement.
genetic:
- name: DRD2
  association: Risk Factor
  notes: Dopamine D2 receptor; primary antipsychotic target; GWAS-implicated gene explaining &gt;20% liability in aggregate with other common variants.
- name: GRIN1
  association: Risk Factor
  notes: NMDA receptor subunit; implicated in glutamatergic dysfunction and cortical disinhibition.
- name: GRIN2A
  association: Risk Factor
  notes: NMDA receptor subunit; involved in NMDA hypofunction on parvalbumin interneurons.
- name: GAD1
  association: Risk Factor
  notes: GAD67 enzyme; epigenetically regulated; contributes to GABAergic dysfunction.
- name: RELN
  association: Risk Factor
  notes: Reelin protein; epigenetically regulated; involved in cortical development and interneuron maturation.
- name: C4A
  association: Risk Factor
  notes: Complement component 4A; drives excessive microglial synaptic pruning during adolescence.
- name: C3
  association: Risk Factor
  notes: Complement component 3; works with C4A in complement-mediated synaptic elimination.
- name: DISC1
  association: Risk Factor
  evidence:
  - reference: PMID:30286368
    supports: SUPPORT
    snippet: DISC1 gene has been shown as a risk factor for schizophrenia in some reports.
    explanation: The meta-analysis confirms associations between specific SNPs in the DISC1 gene and schizophrenia risk.
  - reference: PMID:24056909
    supports: NO_EVIDENCE
    snippet: Questions about DISC1 as a genetic risk factor for schizophrenia.
    explanation: This reference raises questions about the role of DISC1 as a risk factor, implying a lack of consensus.
  - reference: PMID:30285728
    supports: SUPPORT
    snippet: The human DISC1 gene is located on chromosome 1 and is highly associated with schizophrenia and other mental disorders.
    explanation: This study associates the DISC1 gene with schizophrenia among other mental disorders, supporting its role as a risk factor.
  - reference: PMID:20302823
    supports: SUPPORT
    snippet: Modeling the disease in genetically tractable animals is thus a challenging but increasingly important task. In this review, I discuss the potential problems and perspectives associated with modeling schizophrenia in fruit flies, and briefly review the recent studies analyzing the molecular and cellular functions of Disrupted-In-Schizophrenia-1 (DISC1) in transgenic flies.
    explanation: This review highlights the relevance of studying DISC1 functions in the context of schizophrenia.
- name: COMT
  association: Risk Factor
  evidence:
  - reference: PMID:23573605
    supports: SUPPORT
    snippet: &#39;COMT is an enzyme that is distributed widely throughout the brain, but seems to be uniquely relevant to how dopamine affects information-processing in the prefrontal cortex. There is a common variation in the genetic sequence of the COMT gene, which causes a dramatic change in its enzyme activity. In people with schizophrenia, in their healthy siblings, and also in normal controls, the COMT genotype predicts 4% of the variation in human executive cognition and working memory. We have thus identified a genetic mechanism in the human species that affects the efficiency and efficacy of information-processing in the prefrontal cortex. It is, also, a weak genetic risk factor for schizophrenia: in family studies, it increases the risk of schizophrenia by 50-80%.&#39;
    explanation: The COMT gene is identified as a weak genetic risk factor for schizophrenia, increasing the risk by 50-80% in family studies.
- name: NRG1
  association: Risk Factor
  evidence:
  - reference: PMID:16520822
    supports: PARTIAL
    snippet: Our meta-analysis provides support for the association of NRG1 with schizophrenia, but indicates that firmly establishing the role of NRG1 gene in schizophrenia by genetic association requires much larger sample sizes than have hitherto been reported.
    explanation: The meta-analysis found some evidence supporting the association of NRG1 with schizophrenia, but also highlighted the need for larger sample sizes to firmly establish this role.
  - reference: PMID:15162166
    supports: SUPPORT
    snippet: Recently, the gene that encodes neuregulin-1 (NRG1) has been identified as a potential susceptibility gene for schizophrenia, and defects in the expression of erbB3, one of the NRG1 receptors, have been shown to occur in the prefrontal cortex of schizophrenic patients...
    explanation: This reference identifies NRG1 as a potential susceptibility gene for schizophrenia, indicating a genetic association.
  - reference: PMID:20600464
    supports: SUPPORT
    snippet: We mainly focus on genes including:...NRG1 (Neuregulin 1)... Taken together there is converging evidence for the contribution of genes potentially related to alterations in intracellular Ca-homeostasis to the risk of schizophrenia.
    explanation: This review points to NRG1 as a gene potentially related to the risk of schizophrenia.
  - reference: PMID:24968777
    supports: SUPPORT
    snippet: &#39;...It considers models for understanding the role(s) of risk genes, with a particular focus on DTNBP1 and NRG1...&#39;
    explanation: This paper focuses on NRG1 as one of the risk genes associated with schizophrenia.
- name: DTNBP1
  association: Risk Factor
  evidence:
  - reference: PMID:19862852
    supports: SUPPORT
    snippet: This study shows that DTNBP1 is a risk gene for schizophrenia in EAs. Variation at DTNBP1 may modify risk for schizophrenia in this population.
    explanation: This reference provides evidence that DTNBP1 is associated with an increased risk of schizophrenia, particularly in European-Americans.
  - reference: PMID:18474210
    supports: SUPPORT
    snippet: To date, DTNBP1 has provided the greatest evidence of illness modification, as associations with negative and cognitive symptoms and worse outcome have been published in independent samples.
    explanation: This reference elaborates on the association of DTNBP1 with specific clinical features of schizophrenia, further supporting its role as a risk factor.
  - reference: PMID:24968777
    supports: SUPPORT
    snippet: It considers models for understanding the role(s) of risk genes, with a particular focus on DTNBP1 and NRG1, their interactions with environmental factors, and with each other (epistasis).
    explanation: This reference discusses the role of DTNBP1 as a risk gene for schizophrenia within the context of genetic and environmental interactions.
environmental:
- name: Prenatal Stress
  description: Exposure to stress during fetal development may increase risk.
  evidence:
  - reference: PMID:33544627
    supports: SUPPORT
    snippet: we appraise the evidence linking schizophrenia spectrum disorder to prenatal maternal stress.
    explanation: The review provides evidence linking prenatal stress to the risk of schizophrenia spectrum disorder.
  - reference: PMID:26968981
    supports: SUPPORT
    snippet: prenatal stress induces neurodevelopmental alterations in the prefrontal cortex that are expressed as cognitive impairment observed in schizophrenia.
    explanation: The article discusses the association between prenatal stress and neurodevelopmental changes leading to schizophrenia.
  - reference: PMID:26753951
    supports: SUPPORT
    snippet: Findings suggest sex-specific fetal sensitivity to maternal reported daily life stress during pregnancy on risk for SSD, with males appearing to be more vulnerable to the influences of maternal stress during pregnancy.
    explanation: The study found that maternal stress during pregnancy is associated with increased risk of schizophrenia spectrum disorders in offspring, particularly males.
  - reference: PMID:37116354
    supports: SUPPORT
    snippet: Epidemiological findings are rather consistent in supporting the association, albeit they are mitigated by effects of sex and gestational timing.
    explanation: The article evaluates evidence linking prenatal maternal stress with an elevated risk of schizophrenia and discusses the role of microglial activation.
  - reference: PMID:37783300
    supports: SUPPORT
    snippet: Schizophrenia (SCZ) is a multifactorial neurodevelopmental disorder caused by genetic and environmental alterations, especially during prenatal stages.
    explanation: The review states that prenatal environmental alterations, including stress, are associated with an increased risk of schizophrenia.
  exposure_term:
    preferred_term: Prenatal stress exposure
- name: Cannabis Use
  description: Associated with increased risk and earlier onset in genetically predisposed individuals.
  evidence:
  - reference: PMID:24957864
    supports: PARTIAL
    snippet: Although considerable evidence implicates cannabis use as a component cause of schizophrenia, it remains unclear whether this is entirely due to cannabis directly raising risk of psychosis, or whether the same genes that increases psychosis risk may also increase risk of cannabis use.
    explanation: The study suggests that there is an association between cannabis use and schizophrenia, but it indicates that the genetic components might play a significant role, making it partially supportive.
  - reference: PMID:26232243
    supports: SUPPORT
    snippet: Individuals with a history of cannabis abuse had an earlier age at onset by nearly six years.
    explanation: The study provides direct evidence that cannabis use is associated with an earlier age at onset of psychosis.
  - reference: PMID:21068828
    supports: SUPPORT
    snippet: onset is associated with environmental factors such as early life adversity, growing up in an urban environment, minority group position and cannabis use.
    explanation: The association of environmental factors, including cannabis use, supports the idea of increased risk of schizophrenia.
  - reference: PMID:28142064
    supports: SUPPORT
    snippet: The relationship between age at psychosis onset and COMT Val158Met and BDNF Val66Met polymorphisms with early cannabis use as well as those factors associated with early cannabis use were investigated.
    explanation: The study highlights the important role of early cannabis use and genetic polymorphisms in influencing the age at psychosis onset, thereby supporting the statement.
  - reference: PMID:37185055
    supports: SUPPORT
    snippet: Tobacco use was associated with an earlier age at psychosis onset...; however, these results were no longer significant after controlling for cannabis use.
    explanation: The study indicates that cannabis use correlates with an earlier age at onset of psychosis, supporting the statement.
  exposure_term:
    preferred_term: Cannabis exposure
    term:
      id: ECTO:0100005
      label: exposure to cannabis
treatments:
- name: Antipsychotic Medications
  description: Medications such as risperidone, olanzapine, and clozapine to manage symptoms.
  mechanism:
  - name: dopamine D2 receptor antagonism
    description: Primary action through dopamine D2 receptor antagonism
  evidence:
  - reference: PMID:12769630
    supports: PARTIAL
    snippet: With the use of chlorpromazine and other traditional antipsychotics for psychosis, it was soon discovered that the antipsychotic efficacy of this class of medications was closely associated with their ability to block dopamine D(2) receptors in the brain.
    explanation: This reference supports the statement that antipsychotic medications act through dopamine D2 receptor antagonism. It also mentions medications like clozapine, risperidone, and others, but does not specifically mention olanzapine in this context.
  - reference: PMID:14514482
    supports: NO_EVIDENCE
    snippet: &#39;&#39;
    explanation: The title suggests a focus on schizophrenia treatments, but no abstract provided to verify the contents in relation to the detailed mechanism of action of risperidone, olanzapine, or clozapine.
  - reference: PMID:8626371
    supports: PARTIAL
    snippet: The introduction of novel antipsychotic agents, such as clozapine and risperidone, has enhanced the clinicians&#39; ability to manage schizophrenic patients.
    explanation: This supports the usage of clozapine and risperidone but does not detail the mechanism focused on dopamine D2 receptor antagonism.
  - reference: PMID:15846745
    supports: NO_EVIDENCE
    snippet: &#39;&#39;
    explanation: The reference compares the clinical effects of risperidone and olanzapine, but does not provide information on the mechanism of action through dopamine D2 receptor antagonism.
  - reference: PMID:8823348
    supports: PARTIAL
    snippet: Clozapine has shown to be effective in some poor or partially responsive patients in three prospective, random assignment, double-blind trials.
    explanation: Supports effectiveness of clozapine in treatment-resistant patients but does not address dopamine D2 receptor antagonism directly.
  - reference: PMID:32464195
    supports: PARTIAL
    snippet: To improve treatment efficacy during the critical early stages of schizophrenia, we aimed to identify molecular signatures at baseline (T0) for prediction of a positive response to the atypical antipsychotics olanzapine and risperidone after 6 weeks (T6) treatment.
    explanation: This supports the use of olanzapine and risperidone but does not detail the mechanism involving dopamine D2 receptor antagonism.
  - reference: PMID:17845145
    supports: PARTIAL
    snippet: The drug discovery process has focused mostly on targeting D2 dopamine receptors.
    explanation: This reference supports the focus on D2 dopamine receptors in drug discovery, which aligns with the mechanism described.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
- name: Cognitive Behavioral Therapy (CBT)
  description: Therapy aimed at changing maladaptive thought patterns and behaviors.
  evidence:
  - reference: PMID:20880828
    supports: SUPPORT
    snippet: There is good evidence from a considerable number of clinical trials that CBTp has a consistent clinical benefit when used in addition to standard care.
    explanation: This indicates that Cognitive Behavioral Therapy (CBT) is a recognized treatment for schizophrenia that aims at changing maladaptive thought patterns and behaviors.
  - reference: PMID:27335156
    supports: SUPPORT
    snippet: Cognitive behavioural therapy for psychosis and cognitive remediation are 2 psychosocial interventions that have demonstrated positive outcomes for violence in SCZ.
    explanation: This highlights that CBT, which focuses on changing maladaptive thought patterns and behaviors, is effective in treating certain symptoms of schizophrenia.
  - reference: PMID:17716100
    supports: SUPPORT
    snippet: A theoretical analysis of schizophrenia based on a cognitive model integrates the complex interaction of predisposing neurobiological, environmental, cognitive, and behavioral factors with the diverse symptomatology.
    explanation: The statement aligns with the cognitive approach to schizophrenia, which underpins CBT.
  - reference: PMID:31699627
    supports: SUPPORT
    snippet: Cognitive remediation is now widely recognized as an effective treatment for cognitive deficits in schizophrenia.
    explanation: Although this reference focuses on cognitive remediation, it aligns with the efficacy of cognitive therapies like CBT.
  treatment_term:
    preferred_term: behavioral counseling
    term:
      id: MAXO:0000077
      label: behavioral counseling
- name: Social Skills Training
  description: Programs to enhance social interactions and functioning.
  evidence:
  - reference: PMID:16885207
    supports: SUPPORT
    snippet: Social skills training consists of learning activities utilizing behavioral techniques that enable persons with schizophrenia and other disabling mental disorders to acquire interpersonal disease management and independent living skills for improved functioning in their communities.
    explanation: The study states that social skills training helps individuals with schizophrenia to improve functioning in their communities by acquiring interpersonal and independent living skills.
  - reference: PMID:31708048
    supports: SUPPORT
    snippet: Common elements to these interventions include building a therapeutic alliance, recovery orientation, education, and skills training, which can be directed to a range of targets, including problem-solving, communication, social skills, and social cognition.
    explanation: Clinical therapies for first-episode psychosis as part of coordinated specialty care (CSC) include skills training directed at social skills.
  - reference: PMID:23773889
    supports: SUPPORT
    snippet: &#39;METHODOLOGY: Social skills training, cognitive behavioral therapy, cognitive remediation, and social cognitive training therapy paradigms were searched and the extant literature is summarized for each, with particular focus on: 1) the rationale for treatment methodology; 2) particular methods of treatment; and, 3) meta-analytic data regarding their efficacy and/or effectiveness.&#39;
    explanation: This reference indicates that social skills training is a recognized psychosocial method used to treat schizophrenia and discusses its efficacy.
  - reference: PMID:36050663
    supports: SUPPORT
    snippet: Although pharmacological treatments can often lessen the psychotic symptoms that are a hallmark of schizophrenia, they do not lessen the social and cognitive deficits that create the greatest impediments to community engagement and functional recovery.
    explanation: The study compares Cognitive Enhancement Therapy and Social Skills Training (HOPES/SST), highlighting their role in improving social and community functioning.
  - reference: PMID:32614046
    supports: SUPPORT
    snippet: To address this need, we have developed SocialVille-an online, plasticity-based training program that targets SC deficits in schizophrenia...These results provide support for the efficacy of a remote, plasticity-based social cognitive training program in improving SC and social functioning in schizophrenia.
    explanation: The study shows that social cognitive training programs, which could include elements similar to Social Skills Training, improve social functioning in schizophrenia patients.
  - reference: PMID:21860049
    supports: SUPPORT
    snippet: Intention-to-treat analyses found significantly larger pre-post improvements with TAR than with CRT in prosodic affect recognition, ToM, and social competence and a trend effect in global social functioning.
    explanation: The study indicates that training aimed at social cognition, such as TAR, may improve social skills and functions, relevant to social skills training programs.
  treatment_term:
    preferred_term: behavioral counseling
    term:
      id: MAXO:0000077
      label: behavioral counseling
- name: Supportive Therapy
  description: Ongoing support to help manage daily life and stress.
  evidence:
  - reference: PMID:15176765
    supports: SUPPORT
    snippet: This article posits that the positive findings for supportive therapy (ST) in recent trials may indicate an important but undervalued aspect of psychosocial interventions for schizophrenia.
    explanation: The article discusses the benefits of supportive therapy in schizophrenia treatment and emphasizes mechanisms such as the therapeutic alliance and social support, indicating that ongoing support helps manage daily life and stress.
  - reference: PMID:23244011
    supports: SUPPORT
    snippet: The intervention group improved significantly on measures of both PANSS and GAF scores, with large effect sizes at two years follow-up after inclusion. Further, improvement on GAF(function) (p = 0.000) and GAF(symptom) (p = 0.010) significantly favored SPP in combination with TaU over TaU alone.
    explanation: Supportive psychodynamic psychotherapy, a variant of supportive therapy, was found to significantly improve symptoms and functional outcomes, underscoring its role in ongoing support for managing stress and daily life in schizophrenia.
  - reference: PMID:31708048
    supports: SUPPORT
    snippet: Group, individual, and family therapies in CSC aim to help the client and family understand and cope with the experience of psychosis, promote symptomatic and functional recovery and improve quality of life, and support the pursuit of personally meaningful goals of the client.
    explanation: Coordinated specialty care, including supportive interventions, focuses on coping, recovery, and quality of life, indicating the importance of ongoing support.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
- name: Vocational Rehabilitation
  description: Help with gaining and maintaining employment.
  evidence:
  - reference: PMID:8749891
    supports: PARTIAL
    snippet: Most vocational rehabilitation programs have a positive influence on work-related activities, but most have failed to show substantial and enduring impacts on independent, competitive employment.
    explanation: While vocational rehabilitation programs have positive influences on work-related activities, they have not generally shown substantial and enduring impacts on competitive employment.
  - reference: PMID:31327504
    supports: PARTIAL
    snippet: At the end of two years in the service, 829 (70.4%) patients were meaningfully employed and 348 (29.6%) patients were unemployed.
    explanation: Vocational programs have shown promise with a significant portion of patients being gainfully employed, but it does not necessarily indicate maintaining stable employment over long periods.
  - reference: PMID:18715755
    supports: SUPPORT
    snippet: NET training improved vocational outcomes, suggesting the value of combining cognitive remediation with other rehabilitation methods to enhance functional outcomes.
    explanation: Neurocognitive enhancement therapy combined with vocational services showed improved employment outcomes, supporting the positive impact on gaining and maintaining employment.
  - reference: PMID:32393158
    supports: SUPPORT
    snippet: Veterans in the hybrid condition, compared with the AFVP alone, were more likely to find employment, had higher rates of full-time employment, and earned significantly more money over the course of the study.
    explanation: Blended vocational services significantly improved employment outcomes, supporting the effectiveness of vocational rehabilitation in gaining and maintaining employment.
  - reference: PMID:29135426
    supports: SUPPORT
    snippet: Significantly higher employment rate and longer job tenure were found in the ISE group (63.0%, 29.56 wk) compared with the IPS group (50.0%, 25.47 wk) and TVR group (33.3%, 9.91 wk).
    explanation: Integrated supported employment led to higher employment rates and longer job tenure, indicating that such vocational rehabilitation can help with gaining and maintaining employment.
  treatment_term:
    preferred_term: occupational therapy
    term:
      id: MAXO:0001351
      label: occupational therapy
disease_term:
  preferred_term: schizophrenia
  term:
    id: MONDO:0005090
    label: schizophrenia
classifications:
  harrisons_chapter:
  - classification_value: psychiatric disorder
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Schizophrenia.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>